Spero Therapeutics, Inc. 8-KCurrent Reports (8-K / ad hoc)

MD&A

Item 7.01 Regulation FD Disclosure. On July 14, 2026, the Company and Innovent issued a joint press release announcing the entry into the Innovent Agreement. On July 14, 2026, the Company issued a press release announcing the closing of the NPA, the RPA and the transactions contemplated thereby. The full text of each press release is attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated herein by reference. An updated Company presentation is attached as Exhibit 99.3 to this report and is incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K and Exhibits 99.1, 99.2 and 99.3 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.